Business Context and Reporting Period
Company: ANAVEX LIFE SCIENCES CORP.
Filing Type: Form 8-K (Current Report)
Date of Report: March 18, 2019
Reporting Period: Single event date (March 18, 2019)
This filing reports the submission of a prospectus supplement to an effective Form S-3 registration statement (File No. 333-207600). The supplement relates to shares of common stock ($0.001 par value) issuable pursuant to a purchase agreement with Lincoln Park Capital Fund, LLC. The primary purpose of this 8-K is to include the attached opinion of counsel regarding the legality of these shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding securities issuance and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial performance or operational status are reported in this document. The only material event is the filing of the prospectus supplement and the associated legal opinion for the issuance of common stock under the existing purchase agreement with Lincoln Park Capital Fund, LLC.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding business strategy or financial projections.
Risks and Contingencies: No specific risks or contingencies are detailed in this text. The filing focuses solely on the legal validity of the share issuance.
Unusual Items: None reported.
Investor Verification Checklist
- Verify the terms of the purchase agreement with Lincoln Park Capital Fund, LLC referenced in the prospectus supplement.
- Review the attached Exhibit 5.1 (Opinion of Snell & Wilmer, L.L.P.) for legal conditions regarding the share issuance.
- Confirm the total number of shares registered under Form S-3 (File No. 333-207600) to assess potential dilution.
- Check subsequent filings for the actual execution of the share issuance and capital raised.